Trials / Completed
CompletedNCT05265624
The Moran AMD Genetic Testing Assessment Study
A Phase 2 Study of the Value of Pre-symptomatic Genetic Risk Assessment for Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Paul S. Bernstein · Academic / Other
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The goals of this study are: To assess the impact of genetic testing for Age-related Macular Degeneration (AMD) on lifestyle behaviors as measured by systemic and ocular carotenoid status.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Early disclosure of genetic testing results | Early disclosure group receives results of genetic testing at Month 1 |
| BEHAVIORAL | Late disclosure of genetic testing results | Late disclosure group receives results of genetic testing at Month 12 |
Timeline
- Start date
- 2022-08-03
- Primary completion
- 2024-07-12
- Completion
- 2024-07-12
- First posted
- 2022-03-03
- Last updated
- 2025-10-01
- Results posted
- 2025-10-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05265624. Inclusion in this directory is not an endorsement.